Skip to main content
Enwei Pharmaceutical Co., Ltd. logo

Enwei Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 301331 ISIN · CNE100005LC7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2025-08-25 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 301331

About Enwei Pharmaceutical Co., Ltd.

https://www.enwei.com.cn

Enwei Pharmaceutical Co., Ltd. focuses on the research, development, and manufacturing of medicinal products, specializing in Chinese patent medicines and chemical drugs. The company is primarily known for its gynecological health solutions, most notably the Jie Er Yin brand. Its diverse product range covers therapeutic categories such as pediatrics, dermatology, and respiratory care. By combining traditional Chinese medicine with modern pharmacological standards, the company produces various dosage forms including lotions, capsules, and granules. The organization emphasizes clinical efficacy and quality management, targeting a wide range of healthcare needs through ongoing innovation in formulation and drug delivery systems.

Recent filings

Filing Released Lang Actions
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the company's third board of directors' seventh meeting. It includes details about the meeting date, attendance, and voting results on several agenda items, including approval of the 2025 semi-annual report and related fundraising usage reports. The document does not contain the actual semi-annual report or detailed financial statements but references that these reports are disclosed separately on a public information website. The document is short (1254 characters) and serves as a meeting resolution announcement rather than the report itself. Therefore, it fits the category of Board/Management Information (MANG), which covers announcements of board decisions and management matters.
2025-08-25 Chinese
2025年半年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the annual storage and usage of raised funds (募集资金年度存放与使用情况的专项报告) for the half-year period ending June 30, 2025. It includes specific financial figures about the amount raised, usage, interest income, project investments, and compliance with regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange. The document is not a general annual report or earnings release but a specialized report focused on the management and use of capital raised through stock issuance. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length (13,865 characters) and detailed financial data confirm it is the report itself, not just an announcement or certification. Therefore, the correct classification is CAP with high confidence.
2025-08-25 Chinese
2025年半年度非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 85% confidence The document is a detailed tabular summary of non-operating fund occupation and other related party fund transactions for the half-year period of 2025. It includes specific financial figures related to balances, amounts, and interest for the half-year period. The document is relatively short (2338 characters) and focuses on related party transactions and fund occupation rather than comprehensive financial statements or management discussion. It does not appear to be a full interim or quarterly report since it lacks broader financial statements or analysis. It is also not an announcement or certification but a specific financial summary related to related party transactions. Such detailed related party fund occupation disclosures are typically part of regulatory filings or specific reports on related party transactions. Given the specificity and nature of the content, and the absence of broader financial data or management commentary, the best fit is Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2025-08-25 Chinese
关于举行2025年半年度网上业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling of a half-year online earnings presentation (业绩说明会) for the company 恩威医药股份有限公司. It specifies the date and time of the event, the platform for participation, and invites investors to submit questions in advance. The document does not contain actual financial data or detailed financial statements, nor does it present the earnings results themselves. Instead, it is a notice about the upcoming earnings call or presentation. Given the nature of the document as an announcement for an investor presentation event, the most appropriate classification is 'Investor Presentation' (IP). The document length is short and it is not a report publication announcement or regulatory filing. Confidence is high due to clear indicators of an investor presentation announcement.
2025-08-25 Chinese
中信证券股份有限公司关于恩威医药股份有限公司部分募集资金投资项目延期的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from CITIC Securities regarding the delay in certain fundraising investment projects of Enwei Pharmaceutical Co., Ltd. It includes specifics about the fundraising amount, usage plans, investment progress, reasons for project delays, and the impact on the company. It also contains the sponsor's verification opinion and mentions board resolutions approving the delay. The document is focused on the status and management of capital raised through an IPO and its investment projects, which aligns with updates on capital usage and financing activities. It is not a full annual or interim report, nor is it a simple announcement or certification. The content fits best under Capital/Financing Update (CAP) as it deals with fundraising and capital investment project updates.
2025-08-25 Chinese
2025年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2025 年半年度报告全文" which translates to the "2025 Semi-Annual Report Full Text" of Enwei Pharmaceutical Co., Ltd. It contains detailed financial data, management discussion and analysis, company overview, product information, market position, and operational details for the half-year period ending June 30, 2025. The document length is 15,000 characters, indicating a comprehensive report rather than a brief announcement. It includes actual financial statements and substantive financial data and analysis, fulfilling the criteria for an Interim / Quarterly Report. There is no indication that this is merely an announcement or a certification letter, so it should not be classified as RPA or RNS. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2025
2025-08-25 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.